tapebrief
AFL · Q1 2026

AFL · Q2 2026 Earnings

Cautious

Aflac

Reported August 6, 2026

30-second summary

30-second take: Aflac Q2 FY2026 revenue of $4.117B was -1.0% YoY and non-GAAP EPS of $1.75 was -1.7% YoY, with pretax adjusted earnings declining in both operating segments: Japan -6.2% YoY in USD (+3.4% in yen, so the decline is FX-driven) and U.S. -4.6% YoY. Segment revenue tells a different story from segment earnings: Aflac U.S. total adjusted revenues were +2.5% YoY and Aflac Japan was -12.6% in USD (-2.6% in yen). The material tone shift is what's absent: no update to any FY2026 ratio, no forward commentary on Japan sales trajectory, and no transcript available for this brief. Management's Q1 "slightly negative" Q2 warning for the Corporate segment landed (Corporate pretax -$10M), but the silence on forward direction and the ~390bps FX drag on ROE are what define the quarter.

Headline numbers

EPS

Q2 FY2026

$1.75

-0.6% vs est.

Revenue

Q2 FY2026

$4.12B

-1.0% YoY

-2.9% vs est.

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$4.12B$4.16B-1.0%$4.35B-5.3%
EPS$1.75$1.78-1.7%$1.75+0.0%

Guidance

Aflac reported Q2 FY2026 revenue and EPS misses versus consensus, with both operating segments declining YoY (Japan -6.2%, U.S. -4.6%); no forward guidance provided for Q3 or full-year FY2026.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ2 FY2026—$4.117B-2.9% below consensus estimateMissed
EPS (Non-GAAP)Q2 FY2026—$1.75-0.6% below consensus estimate of $1.76Missed
Aflac Japan Segment RevenueQ2 FY2026—YoY growth -6.2%-6.2% YoY contractionMissed
Aflac U.S. Segment RevenueQ2 FY2026—YoY growth -4.6%-4.6% YoY contractionMissed

Segment performance

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Aflac U.S. Pretax Adjusted Earnings$370M——
Aflac Japan Pretax Adjusted Earnings¥118,225M——

Capital & returns

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Adjusted Return on Equity (ROE)12.7%——
Adjusted ROE excl. Foreign Currency Remeasurement16.6%——
Book Value Per Share$60.35——
Adjusted Book Value Per Share$55.01$51.78—

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Aflac U.S. Premium Persistency (12-month rolling)79.4%——
Aflac U.S. New Annualized Premium Sales$349M——

Management tone

Transcript not available for this quarter; tone analysis is inferred from the press release disclosure pattern rather than prepared-remarks language.

Narrative arc: Q3 FY2025 multi-product offensive → Q4 FY2025 margin reset with inflection pushed out → Q1 FY2026 framework holds but near-term caution surfaces → Q2 FY2026 forward guidance goes silent.

The most consequential shift this quarter is what management chose not to say. In Q3 FY2025 the company formalized segment ratio guidance as a market scorecard; in Q4 FY2025 it revised those ratios lower on its first test; in Q1 FY2026 it reaffirmed the revised band and telegraphed a "slightly negative" Q2 for the Corporate segment specifically. This quarter, with pretax earnings declining in both operating segments (Japan -6.2% USD / +3.4% yen; U.S. -4.6%), the press release provides no update to any FY2026 ratio, no Q3 outlook, and no framing of whether the FY bands remain intact. The silence is the signal.

The Q1 warning was narrowly scoped — Max guided Corporate and other pretax earnings to "slightly negative" for Q2. That was accurate: Corporate printed -$10M. What is less clean is the U.S. earnings decline against still-positive U.S. revenue growth (+2.5%), which points to a benefit-ratio step-up rather than a top-line weakness — and no benefit-ratio commentary accompanies the print.

Japan's story is the inverse: yen-basis operating performance held (pretax +3.4% YoY, net earned premiums -3.7% roughly in line with the underlying earned premium trajectory management framed), but USD translation drove the reported segment decline. Without a transcript, the market cannot see management's characterization of FX drag, the Japan benefit ratio's position within the 60–63% band, or the H1 sales pace against the ~¥90B annual offset framework.

Answers to last quarter's watch list

Q2 Corporate segment pre-tax earnings landing within "slightly negative" — Resolved as guided. Corporate and other printed -$10M in Q2, consistent with Max's Q1 characterization. Status: Resolved as guided
Japan benefit ratio Q2 actual underlying basis at or below 61.5% (band midpoint) — The press release does not surface a Q2 Japan benefit ratio disclosure, and no transcript is available to provide the underlying-basis adjustment. This is the third test of the 60–63% framework and the company's decision not to reaffirm the band this quarter is itself a material data point. Status: Not resolved
External reinsurance disclosure cadence and capital consumption — No sized transaction or capital-consumption metric was disclosed on this print. The Q1 framing of reinsurance as "material over time" without a Q2 update keeps this lever in the rhetorical column. Status: Continue monitoring
Japan H1 sales pace vs. analyst-derived ~¥45B half-year run-rate — H1 Japan new annualized premium sales figures not visible in this extract. Japan pretax earnings grew +3.4% YoY in yen with net earned premiums -3.7%, which is consistent with the underlying trajectory but does not confirm sales pace against the ¥90B annual offset. Status: Not resolved
US "buy the bills" sustaining +20% or above — Product-mix growth rates within the U.S. sales figure are not disclosed in a way that isolates the "buy the bills" grouping. With total U.S. NAP sales +2.6% YoY, the earlier +25% narrow-grouping growth from Q1, if sustained, would imply drag elsewhere in the book. Status: Not resolved
Buyback pace: Q2 shares purchased were 8,521K (treasury), consistent with continued capital return. Book value per share grew to $60.35 from Q1's $58.69. Specific dollar pacing was not disclosed in this extract. Status: Partially resolved
Q2 yen rate moves and ESR capital charge sensitivity — No Q2 ESR figure surfaced in this extract. The 16.6% ROE ex-FX remeasurement vs. 12.7% reported implies ~390bps of FX drag, but the ESR/USP sensitivity update is not visible. Status: Not resolved

What to watch into next quarter

Restoration of forward guidance disclosure: watch whether Q3 FY2026 print resumes explicit ratio-band commentary on FY2026 Japan benefit ratio, Japan pre-tax margin, U.S. pre-tax margin, and U.S. net earned premium growth. Continued silence would confirm the ratio-guidance regime introduced in Q3 FY2025 has been effectively abandoned.

U.S. benefit ratio trajectory: the 220bps YoY step-up in the U.S. benefit-to-premium ratio (47.3% → 49.5%) is the load-bearing driver of the U.S. pretax earnings decline against still-growing revenue. Watch whether Q3 reverts or holds elevated.

Japan yen-basis operating trajectory: Q2 yen-basis pretax earnings +3.4% YoY is the cleanest signal from the print. Watch whether Q3 sustains yen-basis growth as the FX overlay continues to translate results lower in USD.

Q2 Japan benefit ratio actual vs. 60–63% band: the underlying figure is the load-bearing test of the revised framework. A Q3 disclosure at or above 63% would trigger the second consecutive downward framework revision in five quarters.

U.S. premium persistency holding at or above 79.4%: the persistency moat is the cleanest structural signal in the U.S. book. Any Q3 step-down would suggest pressure bleeding into customer retention.

FX-adjusted vs. reported ROE gap: the ~390bps gap between 16.6% ex-FX and 12.7% reported quantifies current FX drag. Watch whether the gap narrows on yen moves or persists at this magnitude, which materially affects the return-of-capital pace.

Sources

  1. Aflac Q2 2026 Financial Supplement (SEC): https://www.sec.gov/Archives/edgar/data/4977/000162828026054333/afl063026-financialsupplem.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.